Literature DB >> 19590456

Variation in care in pediatric Crohn disease.

Richard B Colletti1, Robert N Baldassano, David E Milov, Peter A Margolis, Athos Bousvaros, Wallace V Crandall, Karen D Crissinger, Michael A D'Amico, Andrew S Day, Lee A Denson, Marla Dubinsky, Dawn R Ebach, Edward J Hoffenberg, Howard A Kader, David J Keljo, Ian H Leibowitz, Petar Mamula, Marian D Pfefferkorn, M Azim Qureshi.   

Abstract

OBJECTIVES: Variation in medical care can be a barrier to improving clinical outcomes. We aim to describe the variation in care of Crohn disease as provided by a broad sample of pediatric gastroenterologists.
METHODS: Two hundred forty-six Crohn disease patients of 93 pediatric gastroenterologists from 48 practice sites starting treatment with either thiopurine or infliximab were studied. We assessed variation in diagnostic testing that had been performed to establish the diagnosis of Crohn disease and to assess the phenotype, extent, and severity of disease. We also assessed variation in initial thiopurine and infliximab dosage and in nutritional therapy.
RESULTS: Diagnostic studies in which care was uniform included complete blood count, performed in 100% of patients, erythrocyte sedimentation rate and colonoscopy in 96%, and upper endoscopy in 89%. However, imaging of the small bowel had not been performed in 19%, and a stool test for pathogens had not been performed in 29%. Thiopurine methyltransferase (TPMT) had been measured in 61% of patients before treatment with a thiopurine; in 85%, TPMT was normal. Nonetheless, even when TPMT was normal, 40% of patients received an initial dose of thiopurine that was lower than recommended. Testing for tuberculosis before initiating treatment with infliximab was not performed in 30%. In addition, 36% of severely underweight patients were not receiving a multivitamin supplement, supplemental formula, or tube feeding.
CONCLUSIONS: There is variation in diagnostic and therapeutic interventions in the management of pediatric Crohn disease, and gaps exist between recommended and actual care.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19590456     DOI: 10.1097/MPG.0b013e3181919695

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  21 in total

1.  Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.

Authors:  M V Relling; E E Gardner; W J Sandborn; K Schmiegelow; C-H Pui; S W Yee; C M Stein; M Carrillo; W E Evans; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  Quality of care in inflammatory bowel disease.

Authors:  Brijen Shah; Andrew Tinsley; Thomas Ullman
Journal:  Curr Gastroenterol Rep       Date:  2011-02

3.  Accuracy of the medication list in the electronic health record-implications for care, research, and improvement.

Authors:  Kathleen E Walsh; Keith A Marsolo; Cori Davis; Theresa Todd; Bernadette Martineau; Carlie Arbaugh; Frederique Verly; Charles Samson; Peter Margolis
Journal:  J Am Med Inform Assoc       Date:  2018-07-01       Impact factor: 4.497

4.  Inflammatory bowel disease in pediatric patients: Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry.

Authors:  Stephan Buderus; Dietmar Scholz; Rolf Behrens; Martin Classen; Jan De Laffolie; Klaus-Michael Keller; Klaus-Peter Zimmer; Sibylle Koletzko
Journal:  Dtsch Arztebl Int       Date:  2015-02-20       Impact factor: 5.594

Review 5.  Use of thiopurines in inflammatory bowel disease: Safety issues.

Authors:  Anastasia Konidari; Wael El Matary
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

Review 6.  Learning Health Systems as Facilitators of Precision Medicine.

Authors:  L B Ramsey; T Mizuno; A A Vinks; P A Margolis
Journal:  Clin Pharmacol Ther       Date:  2017-03       Impact factor: 6.875

Review 7.  Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments.

Authors:  Volker M Lauschke; Lili Milani; Magnus Ingelman-Sundberg
Journal:  AAPS J       Date:  2017-11-27       Impact factor: 4.009

8.  Effectiveness of anti-TNFα for Crohn disease: research in a pediatric learning health system.

Authors:  Christopher B Forrest; Wallace V Crandall; L Charles Bailey; Peixin Zhang; Marshall M Joffe; Richard B Colletti; Jeremy Adler; Howard I Baron; James Berman; Fernando del Rosario; Andrew B Grossman; Edward J Hoffenberg; Esther J Israel; Sandra C Kim; Jenifer R Lightdale; Peter A Margolis; Keith Marsolo; Devendra I Mehta; David E Milov; Ashish S Patel; Jeanne Tung; Michael D Kappelman
Journal:  Pediatrics       Date:  2014-06-16       Impact factor: 7.124

9.  Variation in Antibiotic Use for Children Hospitalized With Inflammatory Bowel Disease Exacerbation: A Multicenter Validation Study.

Authors:  Matthew P Kronman; Jeffrey S Gerber; Priya A Prasad; Amanda L Adler; Julie A Bass; Jason G Newland; Kavisha M Shah; Danielle M Zerr; Rui Feng; Susan E Coffin; Theoklis E Zaoutis
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-03       Impact factor: 3.164

10.  Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.

Authors:  Brendan M Boyle; Michael D Kappelman; Richard B Colletti; Robert N Baldassano; David E Milov; Wallace V Crandall
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.